ALX Oncology Holdings Inc Ordinary Shares ALXO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ALXO is a good fit for your portfolio.
News
-
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
-
ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference
-
ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
-
ALX Oncology Appoints Allison Dillon as Chief Business Officer
-
ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer
-
ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting
-
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
-
ALX Oncology shares jump 9% after Jefferies upgrade
Trading Information
- Previous Close Price
- $5.60
- Day Range
- $5.29–5.74
- 52-Week Range
- $3.94–17.83
- Bid/Ask
- $5.32 / $6.61
- Market Cap
- $283.95 Mil
- Volume/Avg
- 937,817 / 810,350
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 74
- Website
- https://www.alxoncology.com
Comparables
Valuation
|
Metric
|
ALXO
|
PRLD
|
CLDX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.67 | 0.94 | 2.79 |
Price/Sales | — | — | 300.30 |
Price/Cash Flow | — | — | — |
Price/Earnings
ALXO
PRLD
CLDX
Financial Strength
|
Metric
|
ALXO
|
PRLD
|
CLDX
|
|---|---|---|---|
Quick Ratio | 4.89 | 11.44 | 31.44 |
Current Ratio | 5.21 | 11.64 | 31.77 |
Interest Coverage | −109.38 | — | — |
Quick Ratio
ALXO
PRLD
CLDX
Profitability
|
Metric
|
ALXO
|
PRLD
|
CLDX
|
|---|---|---|---|
Return on Assets (Normalized) | −57.95% | −39.87% | −23.59% |
Return on Equity (Normalized) | −71.23% | −44.79% | −25.21% |
Return on Invested Capital (Normalized) | −71.87% | −43.35% | −25.04% |
Return on Assets
ALXO
PRLD
CLDX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Gpdyznmp | Srm | $628.7 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Llzrjkr | Nbcfc | $122.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Rmqdrjtdh | Mvvywtx | $114.0 Bil | |||
| Moderna Inc
MRNA
| Jszdgzb | Rphq | $45.3 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ydygfdw | Tdzzhw | $31.8 Bil | |||
| argenx SE ADR
ARGX
| Vvpjhbtc | Chm | $25.9 Bil | |||
| BioNTech SE ADR
BNTX
| Bwywbnylw | Vfh | $19.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Dgnzlzt | Gtbhts | $15.5 Bil | |||
| United Therapeutics Corp
UTHR
| Vsmfrdpbl | Sckd | $14.0 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Fbkgnpkxg | Sjcsht | $11.6 Bil |